About Enaltec Pharma Research Private Limited
Data last updated: 16 February 2026
Enaltec Pharma Research Private Limited is a private limited company based in Ambernath, Maharashtra, India, a subsidiary of Enaltec Labs Private Limited. It specialises in pharma contract r and d, a part of the broader pharmaceuticals sector. Incorporated on 18 May 2005, the company has been in operation for over 21 years.
Registered with ROC Mumbai under CIN U24230MH2005PTC153404.
Capital: an authorised share capital of ₹30 Lakh and a paid-up capital of ₹14.02 Lakh. Formerly known as Getz Pharma Research Private Limited and Getz Pharma Private Limited. It is led by directors including Anand Prafulchandra Shah and Vivek Gupta.
Last AGM: 11 August 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No Pl – 11 Midc Addl Ambernath, Maharashtra, India – 421506.
As per the financials filed for FY 2025, the company reported a revenue of ₹5.67 Cr, a decline of 8% compared to the previous year.
The company has a workforce of approximately 40 employees as per the latest available data. It operates as a subsidiary of Enaltec Labs Private Limited.
The company is associated with 1 brand - Enaltec Labs. As per MCA filings, the company has open charges of ₹14.68 Cr and satisfied charges of ₹48.85 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website enaltec.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressPlot No Pl – 11 Midc Addl Ambernath, Maharashtra, India – 421506
-
IndustryPharma, Pharma Contract R&D
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Enaltec Pharma Research Private Limited
Enaltec Pharma Research Private Limited has undergone 3 name changes throughout its history. The company was previously known as Getz Pharma Research Private Limited, Getz Pharma Private Limited, and Enaltec Pharma Research Private Limited. The current legal name is Enaltec Pharma Research Private Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Enaltec Pharma Research Private Limited | Current |
| Getz Pharma Research Private Limited | Previous |
| Getz Pharma Private Limited | Previous |
Associated Brands with Enaltec Pharma Research Private Limited
Enaltec Pharma Research Private Limited operates one associated brand: Enaltec Labs. These brands represent Enaltec Pharma Research Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Non-oncology APIs are developed and manufactured by Enaltec Labs. | enaltec.com |
Competitors & Alternatives of Enaltec Pharma Research Private Limited
Brands and companies operating in the same space as Enaltec Pharma Research Private Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Hikal
|
APIs and intermediates are produced via custom synthesis and research. | Mumbai, India, India | 1988 |
Snapdragon Chemistry
|
Drug discovery and development service provider | Cambridge, United States, United States | 2014 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Business Activity of Enaltec Pharma Research Private Limited
Enaltec Pharma Research Private Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including scientific research and development.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development | ********* |
Auditor Details of Enaltec Pharma Research Private Limited
Enaltec Pharma Research Private Limited is audited by Parikh & Associates for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Parikh & Associates | blur-value | blur-value | blur-value |
Board of Directors of Enaltec Pharma Research Private Limited
Enaltec Pharma Research Private Limited is currently managed by 3 directors, with 16 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Anand Prafulchandra Shah | Managing Director | 12 Sep 2009 | 16 Years 9 Months | Current |
|
Vivek Gupta
Also directs:
Enaltec Labs Private Limited, La Renon Healthcare Private Limited
|
Nominee Director | 14 Feb 2022 | 4 Years 4 Months | Current |
|
Samir Kumar
Also directs:
Enaltec Labs Private Limited, La Renon Healthcare Private Limited
|
Nominee Director | 14 Feb 2022 | 4 Years 4 Months | Current |
Financials of Enaltec Pharma Research Private Limited FY 2025 filings available
Enaltec Pharma Research Private Limited reported revenue of ₹5.67 Cr (down 8% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Enaltec Pharma Research Private Limited
As of FY 2023, Enaltec Pharma Research Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Enaltec Pharma Research Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Oct 2020 | Hdfc Bank Limited | ₹1.18 Cr | Satisfied |
| 16 Mar 2018 | Hdfc Bank Limited | ₹10 Cr | Satisfied |
| 16 Mar 2018 | Hdfc Bank Limited | ₹3.5 Cr | Satisfied |
| 13 Sep 2013 | Bmw India Financial Services Private Limited | ₹32 Lakh | Satisfied |
| 06 Mar 2013 | Icici Bank Limited | ₹3.75 Cr | Satisfied |
Total charge records: 9 View all charges
Employees and EPFO Compliance at Enaltec Pharma Research Private Limited
Enaltec Pharma Research Private Limited has a workforce of 40 employees as of Sep 17, 2024.
Employee Count & EPFO Data of Enaltec Pharma Research Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Enaltec Pharma Research Private Limited
GSTIN & GST Filing Data of Enaltec Pharma Research Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Enaltec Pharma Research Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Enaltec Pharma Research Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Enaltec Pharma Research Private Limited
MSME Payment Delays by Enaltec Pharma Research Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Enaltec Pharma Research Private Limited
Subsidiaries & Group Companies of Enaltec Pharma Research Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Enaltec Pharma Research Private Limited with ownership details.
MCA Filings & Documents of Enaltec Pharma Research Private Limited
MCA Filings & Documents of Enaltec Pharma Research Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Enaltec Pharma Research Private Limited
Frequently Asked Questions about Enaltec Pharma Research Private Limited
Enaltec Pharma Research Private Limited is an active private limited company in the pharma sector based in Ambernath, Maharashtra, India. It was incorporated on 18 May 2005 (21+ years old) and is registered under CIN U24230MH2005PTC153404. The company has 40 employees.
Enaltec Pharma Research Private Limited reported revenue of ₹5.67 Cr for FY 2025 (down 8.00% YoY).
The current directors of Enaltec Pharma Research Private Limited are:
The primary industry of Enaltec Pharma Research Private Limited is pharma. The company specifically operates in pharma contract r and d. The company is currently active in this sector.
Enaltec Pharma Research Private Limited can be reached at the registered office: Plot No Pl – 11 Midc Addl Ambernath, Maharashtra, India – 421506, or through the website enaltec.com.
The authorised capital is ₹30 Lakh, and the paid-up capital is ₹14.02 Lakh.